Protective effect of cilostazol on persistent focal cerebral ischemia in mice

XU Hui-min,YE Yi-lu,SHI Wen-zhen,CHEN Li-ping,ZHANG Wei-ping,WEI Er-qing
DOI: https://doi.org/10.3321/j.issn:1003-3734.2007.12.012
2007-01-01
Abstract:Objective:To determine the dose- and time-dependent protective effect of cilostazol, a phosphodiesterase 3 inhibitor,on focal cerebral ischemia in mice.Methods:Persistent focal cerebral ischemia was induced by middle cerebral artery occlusion(MCAO).Various doses of cilostazol(0.3~30 mg·kg~(-1))and a positive control drug pranlukast(0. 1mg·kg~(-1))were ip injected 30 min before MCAO. The neurological deficits,infarct volume,brain edema,and IgG exudation were determined 24 h after MCAO.In addition,the effect on ischemic injuries was also evaluated when cilostazol was ip injected 1, 2 and 3 h after MCAO.Results:Cilostazol(3 and 10 mg·kg~(-1),ip)and pranlukast(0.1 mg.kg~(-1),ip)in- jected 30 min before MCAO significantly reduced the neurological deficits,infarct volume,brain edema, and IgG exudation.On the other hand,cilostazol(10mg·kg~(-1),ip injected 1 and 2 h after MCAO)signif- icantly reduced the neurological deficits,infarct volume and brain edema.Conclusion:Cilostazol has the protective effect on focal cerebral ischemia in mice.The effective doses are 3~10 mg·kg~(-1),and the therapeu- tic window is within 2 h after ischemia.
What problem does this paper attempt to address?